Physician profile
Michael L Smit
NPI 1952395352
$3,818.24
in general payments reported to CMS, 2019-2025
17 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $18.07 · 2021: $186 · 2022: $451 · 2023: $581 · 2024: $536 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,416.99 | 2019-2025 | Clareon Panoptix Pro, Hydrus Microstent, Clareon |
| Abbvie INC. | $267.06 | 2022-2025 | Xen Glaucoma Treatment System |
| Amgen INC. | $225.24 | 2024-2025 | Tepezza |
| Ivantis, INC | $172.30 | 2019-2021 | |
| Glaukos Corporation | $149.55 | 2022 | |
| Horizon Therapeutics Plc | $128.78 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $103.87 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $64.44 | 2020-2021 | |
| New World Medical,INC. | $61.97 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $45.35 | 2022 | |
| Bausch & Lomb Americas INC. | $41.83 | 2023-2025 | Miebo, Zenlens, Revive |
| Genentech USA, INC. | $27.59 | 2022 | |
| Dompe US, INC. | $27.20 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $26.66 | 2024 | Eylea |
| Harrow Eye, LLC | $22.28 | 2024 | Vevye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $19.43 | 2022 | |
| Biotissue Holdings INC. | $17.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.